Long-term data and subgroup analyses from pivotal EYLEA HD clinical program continue to demonstrate durable efficacy and consistent safety in…
Ad hoc announcement pursuant to Art. 53 LR Idorsia receives a positive opinion from the Committee for Medicinal Products for…
Technology offers timely and cost-efficient infection prevention solution for long-term care amidst industry-wide labor shortagesDALLAS, TX / ACCESSWIRE / April…
Exponential Health, an innovative concierge medicine practice in Michigan, adopts Cardio Diagnostics' AI-driven epigenetic-genetic tests, marking a new era in…
Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanism of ActionDUBLIN, Ireland and BRIDGEWATER, N.J., April 08, 2024 (GLOBE NEWSWIRE) --…
V-INITIATE trial demonstrates that early initiation with Leqvio, prior to guideline-recommended ezetimibe, for ASCVD patients unable to achieve LDL-C goal…
-- Findings Presented on VASCEPA/VAZKEPA Utility in REDUCE-IT Patient Subgroups by Baseline High/Low Lp(a), LDL-C Levels -- -- Lp(a) Results…
LUND, SWEDEN / ACCESSWIRE / April 2, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today reported publication of…
-- Subgroup Analyses from REDUCE-IT® and Mechanistic Data on Icosapent Ethyl(IPE)/Eicosapentaenoic Acid (EPA) Featured at the Meeting -- DUBLIN,…
Zembrace® SymTouch® and Tosymra® will be marketed by Tonix Medicines, Tonix’s wholly-owned commercial subsidiary Commercial capabilities prepare Tonix for the…